Glioblastoma
The most common length of survival following diagnosis is 12 to 15 months, with fewer than 3% to 5% of people surviving longer than five years. Without treatment survival is typically 3 months.
Glioma
Patients with glioma carrying mutations in either "IDH1" or "IDH2" have a relatively favorable survival, compared with patients with glioma with wild-type "IDH1/2" genes. In WHO grade III glioma, "IDH1/2"-mutated glioma have a median prognosis of ~3.5 years, whereas "IDH1/2" wild-type glioma perform poor with a median overall survival of c. 1.5 years. In glioblastoma, the difference is larger. There, "IDH1/2" wild-type glioblastoma have a median overall survival of 1 year, whereas "IDH1/2"-mutated glioblastoma have a median overall survival of more than 3 years.